Risk of Unsuccessful New Product Development and Prolonged Medical-Application Development
First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.
11 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「(14) Prolonged product development • Prolonged product development due to changes in market conditions or fluctuations in customers' performance • Substantial extensions of the development period for products intended for medical applications due to prolonged regulatory approval applications and other factors」
The Group continues to identify the prolonged development of products, including those for medical applications, and delayed recovery of investment as key risks. - FY2018RestatedAnnual report
「The Group places importance on delivering products and services that match market changes and customer needs as quickly as possible and is actively pursuing research and development and capital investment. However, new product development does not necessarily succeed, and even if it does, the products may not match customer needs and may fail to gain acceptance.」
The Group continues to identify the risk of unsuccessful new product development or failure to gain customer acceptance, as well as delayed recovery of investment due to prolonged development and product launches for medical applications. - FY2017RestatedAnnual report
「For products intended for medical applications, customers require a long time to develop and launch products using the Group's products. During this period, changes in market conditions, fluctuations in customers' performance and delays in regulatory approval applications could result in the discontinuation of customer product development or a substantial extension of the development period.」
The Group continues to identify the risk that unsuccessful new product development and prolonged development for medical applications could affect the recovery of research and development and capital investment costs. - FY2016First statedAnnual report
「For products intended for medical applications, customers require a long time to develop and launch products using the Group's products. During this period, changes in market conditions, fluctuations in customers' performance and delays in regulatory approval applications could result in the discontinuation of customer product development or a substantial extension of the development period.」
The disclosure identifies the possibility that recovery of research and development and capital investment costs could be delayed or become impossible as a risk associated with new product development and the development period for medical applications.